Research on Dravet and refractory epilepsy doesn’t stop. On October 3 and 4, we were able to hear live the latest news and advances in the fight against these diseases. We would like to congratulate Basque Centre for Neuroscience Research Achucarro, the University of the Basque Country and ApoyoDravet for the excellent organization of the event.

We had the pleasure of attending the II International Congress on Dravet Syndrome and Refractory Epilepsy in the city of Bilbao. The three organizing entities, the Basque Centre for Neuroscience Research Achucarro, the University of the Basque Country and ApoyoDravet, who once again brought together doctors, researchers, family members, educators and other participants to share knowledge and advance in the modification of these diseases.

As novelties, this year a whole specific afternoon has been incorporated for the knowledge of the medicines and technological devices that are being developed.

Without a doubt, the International Congress on Dravet Syndrome and Refractory Epilepsy has become a benchmark congress in its field.

We were able to share experiences with more than 25 experts from different fields who gave us the latest news during meals and coffees.

MJN made a presentation on how our project approaches the problem of the unpredictability of epilepsy crises and how using the most modern technologies in terms of data processing, use of algorithms and automatic learning Machine Learning systems, it is possible to “teach” different algorithms to assess the risk of suffering an epilepsy crisis at a given time. We were also able to explain how this whole process is carried out in a totally individualized way since at MJN we think that each epileptic seizure is unique.

From here, we would like to congratulate Dr. Luismi Aras for the excellent organization and the treatment we received. We would like to thank Adrián Trejo, responsible for pediatrics at Clínica Corachan, for accompanying us during the 2 days. And to make a special remark about Dr. Antonio Gil-Nagel for his extraordinary presentation on the future of epilepsy treatment and the relaxed conversation we were able to have with him during the congress.

Without a doubt, the International Congress on Dravet Syndrome and Refractory Epilepsy has become a benchmark congress in its field.

Leave a Reply

El usuario que cumplimenta la información requerida en el presente formulario declara estar legitimado para ello y se hace responsable exclusivo de la veracidad e integridad de los datos e información que introduce, exonerando expresamente a MJN NEUROSERVEIS de cualquier responsabilidad que pudiera generarse para esta entidad con ocasión de la información facilitada a través del presente formulario.

Sí, acepto

Save the date

The next Saturday 21st of November at 4 pm, you will be able to know first hand our product: mjn-SERAS.
mjn-SERAS is a healthcare product that sends a warning signal when the risk of epileptic seizures is high, to the affected person and their trusted contacts.

Sign up now!


    mjn-SERAS is a medical device with CE marking according to the European Directive 93/42/EEC and the Royal Decree RD. 1591/2009.
    Contraindications: Do not use the product if you suffer from an infection in the ear canal or if you suffer from a skin lesion in the vicinity of the product's area of influence.
    Considerations: This medical product works with an APP only on Android phones. The results tested are 96% sensitivity and 94% specificity.
    CPSP20103CAT.

    Save the date

    El próximo sábado 21 de noviembre a las 4 de la tarde, podrás conocer de primera mano nuestro producto: mjn-SERAS.
    mjn-SERAS es un producto sanitario que lanza una señal de aviso cuando el riesgo de crisis de epilepsia es elevado, a la persona afectada y a sus contactos de confianza.

    ¡Inscríbete!

      mjn-SERAS es un producto sanitario con marcado CE conforme a la Directiva Europea 93/42/EEC y el Real Decreto RD. 1591/2009.
      Contraindicaciones: No usar el producto en caso de padecer una infección en el canal auditivo o en caso de padecer una lesión cutánea en las proximidades del área de influencia del producto.
      Consideraciones: Este producto sanitario funciona con una APP solo en teléfonos Android. Los resultados testeados son 96% de sensibilidad y 94% de especificidad.
      CPSP20103CAT.